One study shows that individuals tapering off semaglutide were able to maintain their body weight for 6 months
The lawsuit names both Novo Nordisk Inc., the New Jersey-based subsidiary that markets the drug in the United States, and Novo Nordisk A/S, the Danish parent company
Nausea, occasional vomiting, diarrhea, or constipation are frequently reported side effects, typically peaking during the first few weeks and improving with continued use
Through mechanisms that lower LDL and triglycerides, raise HDL cholesterol, and address insulin resistance, semaglutide can support a more balanced lipid profile and healthier heart
Periodic amylase and lipase testing catches early changes, and elevated levels are reason to pause the medication and investigate